GE HealthCare Technologies Inc.
GEHC evidence brief
What we can confirm
- BioSniper Score:
- 8.0 / 10
- Market Cap:
- $28.88B
- Lead Asset:
- achilles insight ultrasonometer (Approved)
What it means
What to watch
Prepared research question
What matters most for GEHC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GEHC
GE HealthCare Technologies Inc. (GEHC) is a publicly traded medical technology and diagnostics company with a focus on imaging, monitoring, and contrast agents, reporting $5.1B in revenue and $389M net income for the quarter ended 2026-03-31 [sec].
Key risk: High debt leverage
BioSniper Score
Based on 6 of 6 signals
Market Cap
$28.88B
Cash Runway
—
Lead Asset
achilles insight ultrasonometer (Approved)
Next Catalyst
Patent_Expiry · Sep 16, 2028Financial data as of Mar 31, 2026.
Tracking 6 pipeline candidates · 14 clinical trials · 1 catalyst for GE HealthCare Technologies Inc..
GE HealthCare Technologies Inc. (GEHC) is a publicly traded medical technology and diagnostics company with a focus on imaging, monitoring, and contrast agents, reporting $5.1B in revenue and $389M net income for the quarter ended 2026-03-31 [sec].
- Cash & equivalents of $2,261.0M as of 2026-03-31 [sec].
- Total revenue of $5,131.0M and net income of $389.0M for the quarter ended 2026-03-31 [sec].
- Shareholders' equity of $10,668.0M and total debt of $10,172.0M as of 2026-03-31 [sec].
- First patient dosed in Phase 2/3 LUMINA trial for mangaciclanol, a manganese-based MRI contrast agent, at Mayo Clinic as of April 2026 [news].
- Approved pipeline candidates include the model 515 neonatal monitor (cardiovascular) and senographe pristina 3d (digital breast tomosynthesis) [pipeline].
What works
- Strong cash position of $2.26B as of 2026-03-31 provides liquidity for R&D and operations [sec].
- Positive net income of $389M in the latest quarter indicates profitability [sec].
- Multiple approved products (e.g., neonatal monitor, breast tomosynthesis system) generate recurring revenue [pipeline].
- Advancing a novel manganese-based MRI contrast agent into Phase 2/3, potentially differentiating from gadolinium-based agents [news].
What to weigh
- Total debt of $10.17B nearly equals shareholders' equity of $10.67B, indicating high leverage [sec].
- The company faces over 485 competitors in the neonatal monitor space alone, suggesting intense market competition [pipeline].
- Patent expiry for FLUTEMETAMOL F-18 on 2028-09-16 could impact related revenue streams [catalyst].
- No disclosed pipeline candidates beyond approved devices and one Phase 2/3 trial, raising questions about future growth drivers [pipeline][news].
From the filings
Quoted directly from source documents.
First patient dosed in Phase 2/3 LUMINA trial for mangaciclanol
“GE HealthCare reached a clinical milestone with the first patient dosed in the Phase 2/3 LUMINA trial for mangaciclanol”
News · April 27, 2026
Approved pipeline candidate: model 515 neonatal monitor
“Pipeline Candidate: model 515 neonatal moniotr Generic Name: MONITOR, CARBON-DIOXIDE, CUTANEOUS Indication: Cardiovascular Phase: Approved”
Patent expiry for FLUTEMETAMOL F-18 on 2028-09-16
“Patent_Expiry: NDA203137”
Catalysts · September 16, 2028
Catalyst timeline
- 2028-09-16 · Patent_Expiry · FLUTEMETAMOL F-18 — Patent expiry for NDA203137; watch for potential generic competition and revenue impact.
Risks & what to watch (3)›
Key risks
- High debt leverage — Total debt of $10.17B nearly equals equity of $10.67B as of 2026-03-31, increasing financial risk [sec].
- Patent cliff for contrast agent — FLUTEMETAMOL F-18 patent expires 2028-09-16, potentially reducing revenue from that product [catalyst].
- Intense competition in core markets — Neonatal monitor faces 485+ competitors; breast tomosynthesis has 2 direct competitors [pipeline].
What to watch
- Progress and results of the Phase 2/3 LUMINA trial for mangaciclanol MRI contrast agent [news].
- Revenue impact from the 2028 patent expiry of FLUTEMETAMOL F-18 [catalyst].
- Debt management and leverage ratios in upcoming quarterly filings [sec].
- Any new pipeline candidates beyond approved devices and the single Phase 2/3 trial [pipeline][news].
Sources: Catalysts · Competitor trials · News · Pipeline · Generated October 6, 2026 · How we verify sources →
Run GE HealthCare Technologies Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GE HealthCare Technologies Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 2.46 · 0% dilution
Lead: Approved
6 candidates
1 upcoming, next in ~703d
8 buys · 0 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 3.0%
- Days to cover
- 2.7
- Shares short
- 12,059,066
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GEHC short interestGovernance
Frequently asked questions
What is the AI investment thesis for GE HealthCare Technologies Inc.?
GE HealthCare Technologies Inc. (GEHC) is a publicly traded medical technology and diagnostics company with a focus on imaging, monitoring, and contrast agents, reporting $5.1B in revenue and $389M net income for the quarter ended 2026-03-31 [sec].
What is GE HealthCare Technologies Inc.'s lead drug candidate?
GE HealthCare Technologies Inc.'s most advanced tracked candidate is achilles insight ultrasonometer (Approved) for Radiology.
What is GE HealthCare Technologies Inc.'s next catalyst?
GE HealthCare Technologies Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA203137" — expected September 16, 2028.
Who is the CEO of GE HealthCare Technologies Inc.?
Mr. Peter J. Arduini is the chief executive officer of GE HealthCare Technologies Inc. (GEHC).
Where is GE HealthCare Technologies Inc. headquartered?
GE HealthCare Technologies Inc. (GEHC) is headquartered in Chicago, IL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.